Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
“We are passionate about doing world-class children’s cancer research which can be taken into the clinic to benefit patients as quickly as possible.
“The ICR’s close partnership with The Royal Marsden and shared site in Sutton has allowed us together to become the UK’s leaders in many aspects of children’s cancer research – including in genetic testing of children with cancer aimed at making precision medicine routine, in the discovery of targeted cancer drugs for children, and in clinical trials of new, experimental treatments.
“We urge the NHS to ensure that in enacting the recommendations there is no disruption to the world-class partnership between paediatric researchers and clinicians at the ICR and The Royal Marsden.
“The ICR has ambitious plans to expand its children’s cancer research within the wider development of The London Cancer Hub on the Sutton site, and we hope the NHS will recognise how important it is to have The Royal Marsden’s excellent paediatric oncology teams on our shared site as part of these plans.”